Click for best price
Blood Cancer Drugs Market Size, Share 2023
| Market size in 2022 |
US$ 64550 million
|
Forecast Market size by 2029 |
US$ 92500 million
|
| Growth Rate |
CAGR of 5.3% |
Number of Pages |
67 Pages |
The global Blood Cancer Drugs market was valued at US$ 64550 million in 2022 and is projected to reach US$ 92500 million by 2029, at a CAGR of 5.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
This report aims to provide a comprehensive presentation of the global market for Blood Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Cancer Drugs. This report contains market size and forecasts of Blood Cancer Drugs in global, including the following market information:
Global Blood Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Blood Chemotherapy Drugs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Blood Cancer Drugs include Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche, and Johnson & Johnson,, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Blood Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Blood Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Blood Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
- Blood Chemotherapy Drugs
- Blood Targeted Therapy Drugs
Global Blood Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Blood Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
- Leukemia
- lymphoma
- Multiple Myeloma
Global Blood Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Blood Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Blood Cancer Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Blood Cancer Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Amgen,
- AstraZeneca PLC,
- Astellas Pharma,
- Bayer AG,
- Bristol-Myers Squibb Company,
- Celgene Corporation,
- Eli Lilly,
- F.Hoffmann-La Roche,
- Johnson & Johnson,
- Novartis
- Pfizer,
- Takeda Pharmaceutical Company Ltd,
- AbbVie
Outline of Major Chapters:
- Chapter 1: Introduces the definition of Blood Cancer Drugs, market overview.
- Chapter 2: Global Blood Cancer Drugs market size in revenue.
- Chapter 3: Detailed analysis of Blood Cancer Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Blood Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Blood Cancer Drugs Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 64550 million
|
| Forecast Market size by 2029 |
US$ 92500 million
|
| Growth Rate |
CAGR of 5.3% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
67 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Blood Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Blood Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Blood Cancer Drugs Overall Market Size
2.1 Global Blood Cancer Drugs Market Size: 2022 VS 2029
2.2 Global Blood Cancer Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Blood Cancer Drugs Players in Global Market
3.2 Top Global Blood Cancer Drugs Companies Ranked by Revenue
3.3 Global Blood Cancer Drugs Revenue by Companies
3.4 Top 3 and Top 5 Blood Cancer Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Blood Cancer Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Blood Cancer Drugs Players in Global Market
3.6.1 List of Global Tier 1 Blood Cancer Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Blood Cancer Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Blood Cancer Drugs Market Size Markets, 2022 & 2029
4.1.2 Blood Chemotherapy Drugs
4.1.3 Blood Targeted Therapy Drugs
4.2 By Type - Global Blood Cancer Drugs Revenue & Forecasts
4.2.1 By Type - Global Blood Cancer Drugs Revenue, 2018-2023
4.2.2 By Type - Global Blood Cancer Drugs Revenue, 2024-2029
4.2.3 By Type - Global Blood Cancer Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Blood Cancer Drugs Market Size, 2022 & 2029
5.1.2 Leukemia
5.1.3 lymphoma
5.1.4 Multiple Myeloma
5.2 By Application - Global Blood Cancer Drugs Revenue & Forecasts
5.2.1 By Application - Global Blood Cancer Drugs Revenue, 2018-2023
5.2.2 By Application - Global Blood Cancer Drugs Revenue, 2024-2029
5.2.3 By Application - Global Blood Cancer Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Blood Cancer Drugs Market Size, 2022 & 2029
6.2 By Region - Global Blood Cancer Drugs Revenue & Forecasts
6.2.1 By Region - Global Blood Cancer Drugs Revenue, 2018-2023
6.2.2 By Region - Global Blood Cancer Drugs Revenue, 2024-2029
6.2.3 By Region - Global Blood Cancer Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Blood Cancer Drugs Revenue, 2018-2029
6.3.2 US Blood Cancer Drugs Market Size, 2018-2029
6.3.3 Canada Blood Cancer Drugs Market Size, 2018-2029
6.3.4 Mexico Blood Cancer Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Blood Cancer Drugs Revenue, 2018-2029
6.4.2 Germany Blood Cancer Drugs Market Size, 2018-2029
6.4.3 France Blood Cancer Drugs Market Size, 2018-2029
6.4.4 U.K. Blood Cancer Drugs Market Size, 2018-2029
6.4.5 Italy Blood Cancer Drugs Market Size, 2018-2029
6.4.6 Russia Blood Cancer Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Blood Cancer Drugs Market Size, 2018-2029
6.4.8 Benelux Blood Cancer Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Blood Cancer Drugs Revenue, 2018-2029
6.5.2 China Blood Cancer Drugs Market Size, 2018-2029
6.5.3 Japan Blood Cancer Drugs Market Size, 2018-2029
6.5.4 South Korea Blood Cancer Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Blood Cancer Drugs Market Size, 2018-2029
6.5.6 India Blood Cancer Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Blood Cancer Drugs Revenue, 2018-2029
6.6.2 Brazil Blood Cancer Drugs Market Size, 2018-2029
6.6.3 Argentina Blood Cancer Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Blood Cancer Drugs Revenue, 2018-2029
6.7.2 Turkey Blood Cancer Drugs Market Size, 2018-2029
6.7.3 Israel Blood Cancer Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Blood Cancer Drugs Market Size, 2018-2029
6.7.5 UAE Blood Cancer Drugs Market Size, 2018-2029
7 Blood Cancer Drugs Companies Profiles
7.1 Amgen,
7.1.1 Amgen, Company Summary
7.1.2 Amgen, Business Overview
7.1.3 Amgen, Blood Cancer Drugs Major Product Offerings
7.1.4 Amgen, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.1.5 Amgen, Key News & Latest Developments
7.2 AstraZeneca PLC,
7.2.1 AstraZeneca PLC, Company Summary
7.2.2 AstraZeneca PLC, Business Overview
7.2.3 AstraZeneca PLC, Blood Cancer Drugs Major Product Offerings
7.2.4 AstraZeneca PLC, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.2.5 AstraZeneca PLC, Key News & Latest Developments
7.3 Astellas Pharma,
7.3.1 Astellas Pharma, Company Summary
7.3.2 Astellas Pharma, Business Overview
7.3.3 Astellas Pharma, Blood Cancer Drugs Major Product Offerings
7.3.4 Astellas Pharma, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.3.5 Astellas Pharma, Key News & Latest Developments
7.4 Bayer AG,
7.4.1 Bayer AG, Company Summary
7.4.2 Bayer AG, Business Overview
7.4.3 Bayer AG, Blood Cancer Drugs Major Product Offerings
7.4.4 Bayer AG, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.4.5 Bayer AG, Key News & Latest Developments
7.5 Bristol-Myers Squibb Company,
7.5.1 Bristol-Myers Squibb Company, Company Summary
7.5.2 Bristol-Myers Squibb Company, Business Overview
7.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Major Product Offerings
7.5.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.5.5 Bristol-Myers Squibb Company, Key News & Latest Developments
7.6 Celgene Corporation,
7.6.1 Celgene Corporation, Company Summary
7.6.2 Celgene Corporation, Business Overview
7.6.3 Celgene Corporation, Blood Cancer Drugs Major Product Offerings
7.6.4 Celgene Corporation, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.6.5 Celgene Corporation, Key News & Latest Developments
7.7 Eli Lilly,
7.7.1 Eli Lilly, Company Summary
7.7.2 Eli Lilly, Business Overview
7.7.3 Eli Lilly, Blood Cancer Drugs Major Product Offerings
7.7.4 Eli Lilly, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.7.5 Eli Lilly, Key News & Latest Developments
7.8 F.Hoffmann-La Roche,
7.8.1 F.Hoffmann-La Roche, Company Summary
7.8.2 F.Hoffmann-La Roche, Business Overview
7.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Major Product Offerings
7.8.4 F.Hoffmann-La Roche, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.8.5 F.Hoffmann-La Roche, Key News & Latest Developments
7.9 Johnson & Johnson,
7.9.1 Johnson & Johnson, Company Summary
7.9.2 Johnson & Johnson, Business Overview
7.9.3 Johnson & Johnson, Blood Cancer Drugs Major Product Offerings
7.9.4 Johnson & Johnson, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.9.5 Johnson & Johnson, Key News & Latest Developments
7.10 Novartis
7.10.1 Novartis Company Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Blood Cancer Drugs Major Product Offerings
7.10.4 Novartis Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.10.5 Novartis Key News & Latest Developments
7.11 Pfizer,
7.11.1 Pfizer, Company Summary
7.11.2 Pfizer, Business Overview
7.11.3 Pfizer, Blood Cancer Drugs Major Product Offerings
7.11.4 Pfizer, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.11.5 Pfizer, Key News & Latest Developments
7.12 Takeda Pharmaceutical Company Ltd,
7.12.1 Takeda Pharmaceutical Company Ltd, Company Summary
7.12.2 Takeda Pharmaceutical Company Ltd, Business Overview
7.12.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Major Product Offerings
7.12.4 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.12.5 Takeda Pharmaceutical Company Ltd, Key News & Latest Developments
7.13 AbbVie
7.13.1 AbbVie Company Summary
7.13.2 AbbVie Business Overview
7.13.3 AbbVie Blood Cancer Drugs Major Product Offerings
7.13.4 AbbVie Blood Cancer Drugs Revenue in Global Market (2018-2023)
7.13.5 AbbVie Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Blood Cancer Drugs Market Opportunities & Trends in Global Market
Table 2. Blood Cancer Drugs Market Drivers in Global Market
Table 3. Blood Cancer Drugs Market Restraints in Global Market
Table 4. Key Players of Blood Cancer Drugs in Global Market
Table 5. Top Blood Cancer Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Blood Cancer Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Blood Cancer Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Blood Cancer Drugs Product Type
Table 9. List of Global Tier 1 Blood Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Blood Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Blood Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Blood Cancer Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Blood Cancer Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Blood Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Blood Cancer Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Blood Cancer Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Blood Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Blood Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Blood Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Blood Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Blood Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Blood Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Blood Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Blood Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Blood Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Blood Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Blood Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Blood Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Blood Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Amgen, Company Summary
Table 31. Amgen, Blood Cancer Drugs Product Offerings
Table 32. Amgen, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Amgen, Key News & Latest Developments
Table 34. AstraZeneca PLC, Company Summary
Table 35. AstraZeneca PLC, Blood Cancer Drugs Product Offerings
Table 36. AstraZeneca PLC, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. AstraZeneca PLC, Key News & Latest Developments
Table 38. Astellas Pharma, Company Summary
Table 39. Astellas Pharma, Blood Cancer Drugs Product Offerings
Table 40. Astellas Pharma, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Astellas Pharma, Key News & Latest Developments
Table 42. Bayer AG, Company Summary
Table 43. Bayer AG, Blood Cancer Drugs Product Offerings
Table 44. Bayer AG, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Bayer AG, Key News & Latest Developments
Table 46. Bristol-Myers Squibb Company, Company Summary
Table 47. Bristol-Myers Squibb Company, Blood Cancer Drugs Product Offerings
Table 48. Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Bristol-Myers Squibb Company, Key News & Latest Developments
Table 50. Celgene Corporation, Company Summary
Table 51. Celgene Corporation, Blood Cancer Drugs Product Offerings
Table 52. Celgene Corporation, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Celgene Corporation, Key News & Latest Developments
Table 54. Eli Lilly, Company Summary
Table 55. Eli Lilly, Blood Cancer Drugs Product Offerings
Table 56. Eli Lilly, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Eli Lilly, Key News & Latest Developments
Table 58. F.Hoffmann-La Roche, Company Summary
Table 59. F.Hoffmann-La Roche, Blood Cancer Drugs Product Offerings
Table 60. F.Hoffmann-La Roche, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. F.Hoffmann-La Roche, Key News & Latest Developments
Table 62. Johnson & Johnson, Company Summary
Table 63. Johnson & Johnson, Blood Cancer Drugs Product Offerings
Table 64. Johnson & Johnson, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Johnson & Johnson, Key News & Latest Developments
Table 66. Novartis Company Summary
Table 67. Novartis Blood Cancer Drugs Product Offerings
Table 68. Novartis Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Novartis Key News & Latest Developments
Table 70. Pfizer, Company Summary
Table 71. Pfizer, Blood Cancer Drugs Product Offerings
Table 72. Pfizer, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Pfizer, Key News & Latest Developments
Table 74. Takeda Pharmaceutical Company Ltd, Company Summary
Table 75. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product Offerings
Table 76. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 77. Takeda Pharmaceutical Company Ltd, Key News & Latest Developments
Table 78. AbbVie Company Summary
Table 79. AbbVie Blood Cancer Drugs Product Offerings
Table 80. AbbVie Blood Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 81. AbbVie Key News & Latest Developments
List of Figures
Figure 1. Blood Cancer Drugs Segment by Type in 2022
Figure 2. Blood Cancer Drugs Segment by Application in 2022
Figure 3. Global Blood Cancer Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Blood Cancer Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Blood Cancer Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Blood Cancer Drugs Revenue in 2022
Figure 8. By Type - Global Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Blood Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Blood Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 16. US Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 28. China Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Blood Cancer Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Blood Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Amgen, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. AstraZeneca PLC, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Astellas Pharma, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bayer AG, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Celgene Corporation, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Eli Lilly, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. F.Hoffmann-La Roche, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Johnson & Johnson, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Novartis Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Pfizer, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. AbbVie Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
